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The  complement  system  plays  a key  role in  host-defense  against  common  pathogens  but  must  be tightly
controlled  to avoid  inﬂammation  and  tissue  damage.  Polymorphisms  in  genes  encoding  two  important
negative  regulators  of the  alternative  complement  pathway,  complement  factor  H  (CFH)  and  complementccepted 19 November 2015
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factor  I (CFI),  are  associated  with  the  risk  for Age-Related  Macular  Degeneration  (AMD),  a leading  cause
of vision  impairment  in  the  ageing  population.  In this  review,  we  will discuss  the  genetic  basis  of  AMD
and  the  potential  impact  of complement  de-regulation  on disease  pathogenesis.  Finally,  we  will highlight
recent  therapeutic  approaches  aimed  at controlling  complement  activation  in patients  with  AMD.
©  2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CComplement BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
Age-related macular degeneration (AMD) is a progressive
egenerative disease of the retina, in which the macula, the area
esponsible for visual acuity and color vision, is affected. AMD
revalence increases with age, and it is estimated that in the
nited States approximately 8 million people ≥55 years old have
by pathologic changes in Bruch’s membrane and RPE that permits
choroidal vasculature to invade the retina (van Lookeren Campagne
et al., 2014). Genetic and environmental factors strongly contribute
to risk for both GA and wet AMD. While polymorphisms in com-
plement proteins control the majority of genetic disease risk, it
is still unclear what pathological processes in the retina are trig-
gered by complement activation. We  would like to refer the readerntermediate or advanced AMD. The development of drusen, extra-
ellular deposits between the retinal pigment epithelium (RPE) and
ruch’s membrane, is an early manifestation of AMD  associated
ith minimal visual acuity impairment. Disease can then advance
o geographic atrophy (GA), characterized by loss of retinal pho-
oreceptors, RPE, and choriocapillaris, or wet AMD, characterized
∗ Corresponding author.
E-mail address: menno@gene.com (M.  van Lookeren Campagne).
ttp://dx.doi.org/10.1016/j.imbio.2015.11.007
171-2985/© 2015 The Authors. Published by Elsevier GmbH. This is an open access article
/).to several excellent recent reviews that discuss the role of com-
plement in AMD  (Clark and Bishop, 2015; Schramm et al., 2014).
In this brief review, we  will primarily focus on complement fac-
tor H (CFH) and complement factor I (CFI) taking center stage
in the genetic basis of disease, and we will address how com-
plement activation can contribute to loss of the choriocapillaris,
RPE and photoreceptors. Finally we will brieﬂy touch on clinical
trials that may  further increase our insights into the clinical out-
come of targeting complement at different levels in the cascade.
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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.1. Complement and the genetic basis of AMD
While the complete spectrum of AMD  risk is yet to be discovered,
t is well accepted that there is a strong genetic contribution. Twin
nd family based epidemiological studies were ﬁrst to identify a
enetic component to AMD  risk. Concordance rates between mono-
ygotic twins are found to be signiﬁcantly higher than di-zygotic
wins (Klein et al., 1994; Meyers et al., 1995). Both population
ased and familial studies have found evidence of sibling corre-
ations, with an estimation that genetic factors can account for
etween 50% and 70% of the total variability in disease risk (Heiba
t al., 1994; Seddon et al., 1997). In the Rotterdam study, the life-
ime risk of late AMD was 50% for an individual of an affected
amily member compared to 12% for relatives of controls, fur-
her solidifying evidence for genetic predisposition (Klaver et al.,
998). Furthermore, it is estimated that genetic risk factors account
or up to 71% of variation in the severity of disease (Seddon
t al., 2005). In this section of the review, we will ﬁrst focus on
he AMD  genetic linkage studies which have identiﬁed multiple
ariants in the complement pathway associated with AMD  sus-
eptibility. We  will then discuss common and rare variant studies,
nd ﬁnally, current knowledge around the CFH and CFI risk loci.
Genetic linkage analyses of AMD  pedigrees identiﬁed multi-
le candidate loci across most chromosomes, demonstrating the
enetically heterogeneous nature of the disorder. Linkage analysis
s usually done using families, where markers spanning the genome
re tested on whether or not they segregate with the phenotype of
nterest. This type of analysis is most effective when the risk allele
s highly penetrant, meaning that if you have the risk allele, you
lso have a high probability of having the phenotype. However,
his study design is generally of limited utility when multiple loci
cross the genome of small to moderate effect size contribute to
he genetic architecture of the disease, as has been found to be
he case with AMD. In all, over ten linkage scans were published
etween 1998 and 2005 identifying loci on almost all chromo-
omes, with the two strongest loci located at chromosome 1q25–31
nd chromosome 10q26 (Gorin, 2012). The discovery of multiple
isk loci spanning the genome which contribute to disease risk
as not limited to the study of AMD, similar results were seen in
esults of linkage studies for most common diseases with complex
e.g., non-Mendelian) modes of inheritance (Altmuller et al., 2001).
In 2005, several studies were simultaneously published identi-
ying and conﬁrming variation in the CFH gene residing at 1q31.3
Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005;
lein et al., 2005) These studies were both following up on the link-
ge peak at 1q25–31 and of a different design, the genome-wide
ssociation study (GWAS). This study design utilizes the human
enome sequence to assemble a panel of dense markers, called
ingle nucleotide polymorphisms (SNPs). In theory, one does not
eed to test all SNPs across the genome as many are linked to
ach other; a subset of tagging SNPs are used in the experiment
o capture the majority of common variation in the genome. In a
WAS, these markers are tested for association with the pheno-
ype of interest. As not all SNPs in the genome are tested, often
he causal SNP is not directly identiﬁed. In general, GWAS points
oward an allele associated with phenotype, and this allele identi-
es a locus of the genome. There can be several candidate genes
n the locus. Functional data around the SNP and previous bio-
ogic knowledge are utilized to narrow down the genes in the locus
o the most likely candidate gene responsible for the association.
Subsequent studies have identiﬁed multiple variants in genes
n the complement pathway (Fig. 1), including complement factor (CFB) and CFI (as with CFH, part of the alternative complement
athway), and complement components 2 and 3 (C2, C3)  (Fagerness
t al., 2009; Gold et al., 2006; Li et al., 2006; Maller et al., 2006;
ates et al., 2007). Over time, AMD  GWAS have increased greatlyunobiology 221 (2016) 733–739
in size (both with regards to study population and the number of
SNPs tested), and in 2013, the AMDGene consortium published the
largest genetic analysis of AMD  risk to date comprised of >17,000
cases and >60,000 controls (Fritsche et al., 2013) (Fig. 1). This
study conﬁrmed the genetic associations at the CFH, CFI,  CFB, C2
and C3 loci as well as several other non-complement related loci.
Recently, studies utilizing rare variant arrays and next gener-
ation sequencing platforms have been published. These studies
allow investigators to incorporate information on rare (the minor
allele occurring in <1% of the population), and sometimes private
(in the case of next generation sequencing studies) variation seen
in individuals. Several of these identify rare, amino acid changing
variation in known AMD  risk associated complement genes, and
newly associated complement component 9 (C9) as being strongly
associated with risk of AMD  (Helgason et al., 2013; Raychaudhuri
et al., 2011; Seddon et al., 2013; van de Ven et al., 2013; Zhan
et al., 2013). In summary, common and rare variant studies have
identiﬁed multiple SNPs associated with AMD  risk in complement
genes CFH, CFI, CFB, C2,  C3 and C9.  Here we will focus the remainder
of this portion of our review on negative regulators CFH and CFI.
1.2. CFH
Complement factor H (CFH) was  the ﬁrst gene in the comple-
ment pathway to be associated with risk of AMD, and as a result
is the most highly studied. As previously mentioned, in 2005,
several groups simultaneously reported an association of a non-
synonymous variant in the CFH gene with AMD  risk (Edwards
et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al.,
2005). This variant alters a tyrosine residue to a histidine residue
at position 402 (Y402H) with consequences for its function. The
histidine residue leads to impaired regulation of the alternative
C3 convertase through decreased binding afﬁnity of several lig-
ands (Khandhadia et al., 2012). Inherited alleles of this variant are
additive for AMD  risk, and confer two  times higher risk per copy
in patients of European descent (Sofat et al., 2012). This variant
exists in all major ancestral populations, although in differing fre-
quency. While this variant is common in European populations
with a minor allele frequency (MAF) of 0.282 in the European
HapMap samples, it is relatively rare in Asian populations with MAF
of 0.057 and 0.067 in the HapMap of Japanese and Han Chinese
respectively (The International HapMap Project, 2003). However,
this variant still confers risk in Asian populations, with an OR
similar to that of Europeans in recent meta-analyses implying
that the SNP’s functionality is similar between ancestral popula-
tions (OR ∼2 per allele) (Kondo et al., 2011; Quan et al., 2012).
While the Y402H variant is the most widely studied, it should
be noted that the CFH locus is highly complex, with multiple
independent SNPs and haplotypes conferring both risk and pro-
tection from AMD. In the large common variant meta-analysis
from the AMDGene consortium, two  independent signals were
detected (Fritsche et al., 2013). Additionally, there are several
genes related to CFH (CFHR1-5) that are located immediately adja-
cent to CFH at this locus. A common deletion exists encompassing
CFHR1 and CFHR3.  This deletion is independent of the Y402H vari-
ant, and protective of AMD  risk; subjects homozygous for the
deletion comprise 1.1% of AMD  cases and 5.7% of controls and
have no detectible CFHR1 or CFHR3 in serum (Hageman et al.,
2005; Hughes et al., 2006). Similarly to Y402H, the deletion exists
in all major ancestral populations with differing frequency. It
is most common in those of African descent (frequency = 0.159)
compared to others (European = 0.047, Chinese = 0.022) (Hageman
et al., 2006). While the body of literature on CFHR1-5 is not
as strong as that of CFH, it has been shown that they all bind
to complement component C3b (Skerka et al., 2013). In vitro
studies have shown CFHR3 to compete with CFH for binding to
M. van Lookeren Campagne et al. / Immunobiology 221 (2016) 733–739 735
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he  Table are based on (Fritsche et al., 2013). OR = odds ratio, SNP = singlenucleotide
3b and to also act as co-factor to CFI, similar to CFH (Fritsche
t al., 2010). In the absence of CFHR3, as in subjects homozy-
ous for the deletion, CFH binding to C3b is increased. As CFH is
 more potent regulator of complement activation than CFHR3, an
ncrease in CFH binding results in reduced complement activity,
onsistent with the protective odds ratio seen for the deletion.
Certain rare coding (non-synonymous) variation exists within
FH that is associated with AMD  risk. One study identiﬁed a
ighly penetrant CFH mutation, R1210C, in a sequencing study
f 2423 AMD  cases and 1122 controls. This variant was seen
n 40 cases and only 1 control (p = 7.0 × 10−6) (Raychaudhuri
t al., 2011). Exome sequencing of Amish families identiﬁed a
503A variant not seen in non-Amish individuals of European
escent. This variant was signiﬁcantly associated with risk of
MD (p = 9.27 × 10−13) (Hoffman et al., 2014). Additional rare
ariants that affect the negative regulatory function of CFH pre-
ispose to early-onset AMD  (Yu et al., 2014). Together, these
tudies show that exome sequencing of AMD  patients will iden-
ify risk alleles not found through common variant studies.
.3. CFI
Canonically, the CFI locus (OR ∼1.14) has not been consid-
red a major driver of AMD  pathology compared to other risk
oci containing AMD  associated common variants of larger effect
izes such as CFH (Fagerness et al., 2009; Fritsche et al., 2013).
wo SNPs in this locus have been identiﬁed from large GWAS
tudies. This locus was ﬁrst identiﬁed by SNP rs10033900 in a
tudy by Fagerness et al. (2009), however, not all groups were
ble to replicate this ﬁnding (Cipriani et al., 2012). Considering the
elatively low odds ratio for this SNP, the discrepancy is not sur-
rising and is highly dependent on sample size needed to detect
 statistically signiﬁcant difference between cases and controls.
s such, larger study populations were needed to conﬁrm the
ocus. The large AMDGene consortium meta-analysis identiﬁed
s4698775 as the strongest SNP at the locus, however, this SNP
s not strongly correlated with rs10033900 (r2 = 0.312; D’ = 0.749).loci in each of the complement pathways. fP = properdin, fB = factor B. Numbers in
orphism, P = P-value.
While common variant studies have not shown CFI to be as
strong of an AMD  risk gene as CFH, rare variant studies have shed
much light on its impact on AMD  risk. A recent next-generation
sequencing study has shown that rare CFI coding variation is
enriched approximately four-fold in AMD  cases compared with
controls (Seddon et al., 2013). In this study the authors sequenced
681 genes either associated with AMD  risk, or related biologically
to AMD  risk genes. CFI had the strongest enrichment of overall rare
coding variation in cases compared to controls (controls = 2.30%,
cases = 7.77%; p = 1.6 × 10−8). We have replicated these data. We
sequenced 1177 controls and 1386 advanced AMD  cases and saw
similar enrichment (controls = 2.10%, cases = 5.34%; p = 4.0 × 10−5;
unpublished data). A second study has demonstrated this type of
variation may  have a major impact on AMD  risk (p = 3.9 × 10−6;
odds ratio 22.20) (van de Ven et al., 2013). Finally, rare variants
in CFI result in lower plasma CFI levels and hence lower regula-
tory activity of the alternative pathway (Kavanagh et al., 2015)
1.4. Complement activation affecting choroid, RPE and
photoreceptors
The retinal pigment epithelium (RPE) forms a monolayer of
highly specialized neuroectodermally derived pigmented cells
located between the neurosensory retina and the vascular choroid
(Fig. 2). The RPE mediates functions that are essential for nor-
mal  outer retinal physiology, including phagocytosis of shed
photoreceptor outer segments (POS), participation in the visual
cycle, maintenance of the outer blood—retinal barrier, secretion of
growth factors, water transport and regulation of bidirectional ion
and metabolic transport between the retina and choroid (Strauss,
2005). The RPE is in close proximity to the choriocapillaris, a
vascular structure critically important for the supply of oxygen
and nutrients to the RPE and neural retina. In many aspects, the
choroid is the site where pathological features characteristic of
AMD ﬁrst manifest. Membrane attack complex is deposited in the
foveal choroid throughout life and signiﬁcantly increases with age-
ing and in AMD  (Whitmore et al., 2015). Drop-out of choroidal
736 M. van Lookeren Campagne et al. / Immunobiology 221 (2016) 733–739
Fig. 2. Loss of RPE barrier function and Bruch’s membrane damage leads to increased access of complement proteins to the outer neural retina. Reduced expression of
m E cells
a d C4 
i  RPE.
e
s
r
o
D
e
t
p
i
m
i
b
A
c
e
t
t
i
t
c
l
r
l
a
s
i
o
p
w
a
i
p
l
C
b
a
C
l
membrane regulators of complement activation facilitates complement attack on RP
naphylatoxins C3a, C4a and C5a at the choriocapillaris-Bruch’s-RPE interface, C3 an
ncreased presence of phagocytic cells, promotes further loss of photoreceptors and
ndothelial cells and resulting atrophy of the choroid could have
evere impact on the supply of oxygen and nutrition to RPE cells,
esulting in the death of RPE and the photoreceptors that depend
n a healthy choroid and choriocapillaris (Whitmore et al., 2015).
rusen, extracellular deposits located between the retinal pigment
pithelial (RPE) basal lamina and the inner collagenous layer of
he elastin-containing Bruch’s membrane, contain several com-
lement proteins, including C3, C5 and its activation products,
ndicating the possibility for local complement-mediated inﬂam-
ation (Anderson et al., 2010; Hageman et al., 2001). Indeed,
n postmortem tissue studies, accumulation of macrophages has
een associated with complement activation (Wang et al., 2015).
 number of studies performed using monolayers of fetal cell
ultures or human tissues have pointed to a direct pathogenic
ffect of complement on RPE cells in combination with exposure
o oxidative stress. The retina is particularly receptive to oxida-
ive damage because of high oxygen tension, marked exposure to
rradiation and a high proportion of polyunsaturated fatty acids in
he photoreceptor outer segments (POS). Oxidative stress reduces
omplement inhibition on the RPE cell surface, resulting in sub-
ytic complement activation initiated following natural antibody
ecognition of neoepitopes on RPE cells and loss of transepithe-
ial resistance (Joseph et al., 2013). Complement is then further
mpliﬁed through the complement alternative pathway (AP). Con-
tant light exposure and exposure to oxidative stress can also
ndirectly contribute to complement activation through lipid per-
xidation. Malondialdehyde (MDA) is a common lipid peroxidation
roduct that accumulates in AMD. The CFH polymorphism Y402H,
hich is strongly associated with AMD, markedly reduces the
bility of CFH to bind MDA  (Weismann et al., 2011) indicat-
ng a link between oxidative stress and complement activation.
Loss of complement regulators could potentially impair com-
lement inhibition on RPE cells and contribute to pathological
esions in the outer retina and Bruch’s membrane. CD46 and
D59 are important retinal pigment epithelium (RPE) cell mem-
rane complement regulators that block complement activation
nd membrane attack formation on the cell surface. CD46 and
D59 were decreased in RPE cells following exposure to oxidized
ow-density lipoproteins (oxLDLs), which are found in Bruch’s
embrane in AMD  (Ebrahimi et al., 2013). Loss of CD46 and CD59 and photoreceptors in the lesion core and lesion border. Generation of complement
opsonization and formation of the membrane attack complex (MAC), together with
was mediated through release in exosomes and apoptotic particles
(Ebrahimi et al., 2014). In parallel, products of the photo-oxidation
of bis-retinoid lipofuscin pigments accumulate inside the RPE cells
over the lifetime of an individual and could serve as a trigger for
the complement system, predisposing the macula to disease and
contributing to chronic inﬂammation (Zhou et al., 2006, 2009).
Compromised function of the RPE will result in a secondary
loss of sensory retina function. The neurosensory retina itself, in
particular the photoreceptor outer segments, could be prone to
complement attack due to low levels of complement regulators
expressed on these cells (Fett et al., 2012) (Fig. 2). An outstanding
question is which complement effector molecules are important
for loss of RPE and photoreceptor function. Release of the anaphy-
latoxins (C3a, C4a and C5a) (Haas and van Strijp, 2007) may  act
as chemoattractants for phagocytic cells that in themselves could
have a pathogenic role once they have migrated to the vulnerable
photoreceptor outer segment layer. Macrophages could contribute
to photoreceptor loss by phagocytosis of phosphatidylserine-rich
photoreceptor outer segments and by producing cytokines and
growth factors that can further affect retina function. C3b, iC3b
and C4b are important opsonins and, when present in the outer
retinal layers, could target otherwise healthy RPE cells or photore-
ceptor outer segments for phagocytosis. Finally, formation of the
membrane attack complex can perforate the plasma membrane of
choroidal endothelial cells, RPE cells or cells in the neurosensory
retina contributing to cell loss (Morgan, 1999). Which of these com-
plement effector functions contribute to AMD  disease progression
is unclear. Results from clinical trials that either selectively target
the alternative pathway, all pathways at the C3 convertase level or
all pathways at the C5 convertase level will improve our knowl-
edge about the critical effector molecules that drive elimination
of RPE cells and photoreceptors and promote neo-angiogenesis.
1.5. Complement activation and environmental factors
Environmental factors like smoking and diet can further inﬂu-
ence the balance between complement activation and inhibition
in the eye. Exposure to cigarette smoke results in oxidative stress
and complement activation via the AP (Kunchithapautham et al.,
2014). An association between diet, speciﬁcally the intake of
 / Imm
s
m
i
m
w
f
1
R
v
h
m
i
t
a
i
h
i
o
i
t
e
a
(
A
p
t
t
i
C
p
t
c
t
h
d
e
p
s
t
6
(
o
c
m
i
a
i
d
a
(
1
a
c
e
e
a
o
f
R
iM. van Lookeren Campagne et al.
peciﬁc types of fat, and increased risk of AMD  caused by poly-
orphisms in CFH, has been proposed (Wang et al., 2014) and
s thought to be due to toxic lipid peroxidation. Thus environ-
ental factors (high-fat diet, smoking, lack of exercise) combined
ith increased oxidative stress may  act in concert with genetic
actors to precipitate local complement activation in the macula.
.6. Complement inhibition in the clinic
While complement activation may  contribute to photoreceptor,
PE and choriocapillaris loss in AMD, intervention at any indi-
idual molecular pathway may  not be sufﬁcient to completely
alt the progression to GA. Approaches that are not comple-
ent related and are currently being evaluated in clinical studies
nclude trophic growth factors that preserve RPE cells and pho-
oreceptors, prevention of oxidative damage, reduction in the
ccumulation of retinal toxins, and alleviation of complement-
ndependent inﬂammatory damage (Holz et al., 2014). Based on
uman genetics as well as pathophysiological features of AMD  that
mplicate complement activation, various companies have devel-
ped potent inhibitors that have been, or are currently being tested
n clinical trials. LFG316 (Novartis Pharmaceutical) is an antibody
hat inhibits activation of complement C5. It is currently being
valuated in a phase 2 study in patients with GA as a mono ther-
py and in combination with CLG561, an inhibitor of properdin
ClinicalTrials.gov identiﬁers NCT01527500 and NCT02515942).
PL-2, a compstatin analoge (Apellis, Louisville, KY) is a cyclic
eptide which prevents the conversion of C3 to C3a and C3b,
hereby inhibiting all 3 major pathways of complement activa-
ion; Phase 2 trials in patients with geographic atrophy are being
nitiated. Eculizumab (SOLIRIS, Alexion Pharmaceutials, Cheshire,
T) is a humanized monoclonal antibody that inhibits the com-
lement cascade at C5, preventing the formation and release of
he downstream anaphylatoxin C5a and the formation of the
ytolytic membrane attack complex. Eculizumab is a FDA approved
reatment for paroxysmal nocturnal hemoglobinuria and atypical
emolytic-uremic syndrome, both complement-mediated disor-
ers. The phase 2 COMPLETE study assessed the safety and
fﬁcacy of eculizumab administered by intravenous infusionto
atients with GA (NCT00935883). Results from the COMPLETE
tudy reported that eculizumab was well tolerated; however,
here was no evidence of a treatment beneﬁt at the predeﬁned
 month endpoint (Yehoshua et al., 2014, 2011). Lampalizumab
Genentech/Roche, South San Francisco, CA) is a recombinant, mon-
clonal antibody fragment directed against complement factor D. A
ompleted phase 1a study evaluated the safety, tolerability, phar-
acokinetics and immunogenicity of single ascending doses of
ntravitreal lampalizumab in patients with GA (Do et al., 2014). In
ddition, the completed MAHALO phase 2 study (ClinicalTrials.gov
dentiﬁer, NCT01229215) assessed the safety, tolerability and evi-
ence of activity of lampalizumab in GA (manuscript submitted),
nd phase 3 trials with lampalizumab in GA are currently ongoing
ClinicalTrials.gov identiﬁers, NCT02247479 and NCT02247531).
.7. Concluding remarks
Although the different forms of AMD  share common genetic
nd pathological features, there are likely unique biological pro-
esses that predispose to each deﬁned disease manifestation. For
xample, clinical studies have demonstrated that there is consid-
rable variability in disease progression and therapeutic responses
mong patients. The need for speciﬁc population-tailored therapies
r precision medicine approaches that take into account potential
or progression, imaging features and genetics is highly desired.
ecent preclinical and clinical studies on the role of complement
n the pathophysiology of AMD  have signiﬁcantly improved ourunobiology 221 (2016) 733–739 737
understanding of the disease but we  are still in the early stages
of identifying the appropriate therapeutic targets in the comple-
ment pathways. Continuing preclinical and clinical investigations
will be essential to addressing this major unmet medical need.
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